A bupropion smoking cessation clinical trial for cancer patients

Schnoll, Robert A.; Martínez, Emmanuelle; Tatum, Kristina L.; Weber, Dorothy M.; Kuzla, Natalie; Glass, Marcella; Ridge, John A.; Langer, Corey J.; Miyamoto, Curtis; Wileyto, E. Paul; Leone, Frank T.

doi:10.1007/s10552-010-9507-8

Cited by 66 publications

(69 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ten RCTs 5,15,16,[66][67][68][69][70][71][72] and 3 PC studies 21,73,74 met the inclusion criteria (Figure 1).…”

Section: Literature Searchmentioning

confidence: 99%

“…Published studies ( Table 1) were single-center 15,16,21,66,[68][69][70]72,73 or multicenter. 4,5,67 There were a total of 1301 patients.…”

Section: Trial Characteristicsmentioning

confidence: 99%

“…Studies were evaluated in 2 groups based on follow-up duration. The group with the shorter follow-up period (n = 6) had a mean follow-up of 5 weeks, 15,21,66,[68][69][70][71][72][73][74] and the longer follow-up group (n = 7) was followed for at least 6 months. 4,5,16,67 In the second group, pooled rates were calculated from the 6-month abstinence rates in all studies except 1, 4 which reported a 12-month rate ( Table 4).…”

Section: Tobacco Cessation Rates and Follow-upmentioning

confidence: 99%

See 2 more Smart Citations

Smoking Cessation Interventions and Cessation Rates in the Oncology Population: An Updated Systematic Review and Meta‐Analysis

Nayan

Gupta

Strychowsky

et al. 2013

Otolaryngol.--head neck surg.

104

107

View full text Add to dashboard Cite

Objectives. To evaluate tobacco smoking cessation interventions and cessation rates in the oncology population through a systematic review and meta-analysis.Data Sources. The literature was searched using PubMed, Google Scholar, Medline, EMBASE, and the Cochrane Library (inception to October 2012) by 3 independent review authors.Review Methods. Studies were included if they were randomized controlled trials (RCTs) or prospective cohort (PCs) studies evaluating tobacco smoking cessation interventions with patients assigned to a usual care or an intervention group. The primary outcome measure was smoking cessation rates. Two authors extracted data independently for each study. When applicable, disagreements were resolved by consensus.Results. The systematic review identified 10 RCTs and 3 PCs. Statistical analysis was conducted using StatsDirect software (Cheshire, UK). Pooled odds ratios (ORs) for smoking cessation interventions were calculated in 2 groups based on follow-up duration. The therapeutic interventions included counseling, nicotine replacement therapy, buproprion, and varenicline. Smoking cessation interventions had a pooled odds ratio of 1.54 (95% confidence interval [CI], 0.909-2.64) for patients in the shorter follow-up group and 1.31 (95% CI, 0.931-1.84) in the longer follow-up group. Smoking cessation interventions in the perioperative period had a pooled odds ratio of 2.31 (95% CI, 1.32-4.07). Conclusion.Our systematic review and meta-analysis demonstrate that tobacco cessation interventions in the oncology population, in both the short-term and long-term follow-up groups, do not significantly affect cessation rates. The perioperative period, though, may represent an important teachable moment with regard to smoking cessation. C igarette smoking and alcohol consumption synergistically increase the risk of developing squamous cell carcinoma of the head and neck.1,2 Tobacco carcinogens also further advance the molecular progression of squamous cell carcinomas of the head and neck.1,2 Cigarette smoking has been related to approximately 90% of diagnoses of lung cancer in countries with a high prevalence of smoking. Furthermore, the increased incidence of lung cancer from smoking is proportional to the length and intensity of smoking history.3 Smoking cessation is particularly important for patients who have smoking-related cancers, such as head and neck or lung cancer. 3,4 Persistent tobacco smoking in the oncology population has a multitude of adverse effects during the treatment of the malignancy, increases the risk of a recurrence or a second primary tumor, and reduces survival. 5,6 These risks are particularly apparent in patients with head and neck or lung cancer. Cigarette smoking also increases the perioperative risks of general anesthesia, poor wound healing, and cardiovascular events. 7-9490886O TOXXX10

show abstract

“…Ten RCTs 5,15,16,[66][67][68][69][70][71][72] and 3 PC studies 21,73,74 met the inclusion criteria (Figure 1).…”

Section: Literature Searchmentioning

confidence: 99%

“…Published studies ( Table 1) were single-center 15,16,21,66,[68][69][70]72,73 or multicenter. 4,5,67 There were a total of 1301 patients.…”

Section: Trial Characteristicsmentioning

confidence: 99%

Section: Tobacco Cessation Rates and Follow-upmentioning

confidence: 99%

See 1 more Smart Citation

Smoking Cessation Interventions and Cessation Rates in the Oncology Population: An Updated Systematic Review and Meta‐Analysis

Nayan

Gupta

Strychowsky

et al. 2013

Otolaryngol.--head neck surg.

104

107

View full text Add to dashboard Cite

show abstract

“…Other studies have found that untreated depression increases noncompliance with difficult and complex chemotherapy and radiation treatment regimens (54,55). Psychological distress has also been associated with noncompliance with some National Comprehensive Cancer Network (NCCN)-recommended cancer surveillance screening behaviors in long-term cancer survivors (56) and with engaging in health-enhancing behaviors such as exercise (57) and smoking cessation (58).…”

Section: Psychological Risk Factors For Adverse Late Effectsmentioning

confidence: 99%

Survivors at Higher Risk for Adverse Late Outcomes Due to Psychosocial and Behavioral Risk Factors

Carmack

Basen-Engquist

Gritz

2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Cancer survivors face significant morbidity and mortality associated with their disease and treatment regimens, some of which can be improved through modifying behavioral and psychosocial risk factors. This article examines risk factors for adverse late effects that contribute to morbidity and mortality in cancer survivors, provides a literature review on interventions to modify these risks factors, and summarizes the national recommendations and associated current practices for identifying and managing these risk factors. Finally, future directions for research and clinical practice are discussed. Cancer Epidemiol Biomarkers Prev; 20(10); 2068-77. Ó2011 AACR.

show abstract

“…Patients with depression reported significantly lower abstinence rates than those without depression (OR=0.14; 95% CI, 0.02-0.80). For depressed patients, bupropion also reduced withdrawal symptoms and improved quality of life [23].…”

Section: Bupropion For Tobacco Dependence Treatment In Depressed Smokersmentioning

confidence: 94%

Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update

Hays

McFadden

Ebbert

2011

Curr Atheroscler Rep

View full text Add to dashboard Cite

Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.

show abstract

A bupropion smoking cessation clinical trial for cancer patients

Cited by 66 publications

References 50 publications

Smoking Cessation Interventions and Cessation Rates in the Oncology Population: An Updated Systematic Review and Meta‐Analysis

Smoking Cessation Interventions and Cessation Rates in the Oncology Population: An Updated Systematic Review and Meta‐Analysis

Survivors at Higher Risk for Adverse Late Outcomes Due to Psychosocial and Behavioral Risk Factors

Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update

Contact Info

Product

Resources

About